TechAviv

Dimer Health specializes in post-acute care, supporting patients post-hospital discharge. Their platform facilitates at-home recovery, offering personalized care plans, telehealth services, and remote monitoring by a team of medical professionals.

Remepy is a biotechnology research company based in Ramat Gan, Tel Aviv, focused on developing hybrid drugs that integrate software applications with traditional pharmaceuticals. Founded in 2022, Remepy aims to enhance drug efficacy by combining medical treatments with tailored software solutions that activate specific brain mechanisms. This innovative approach seeks to create synergetic effects at the molecular level, allowing pharmaceutical companies to offer software-drug combinations that improve immune system responses and overall drug safety. By pioneering this unique blend of technology and medicine, Remepy positions itself at the forefront of the evolving landscape of healthcare solutions.

Somite.ai is a venture-backed company aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies. Somite's AI platform, AlphaStem, fuels a virtuous cycle: It enables new cell therapies, generating massive data that further improve the platform, empowering even faster therapy creation with broader applications. The company's pipeline includes the promising SMT-M01 program for Duchenne muscular dystrophy (DMD) and the SMT-B01 program for metabolic disorders. Incorporated in Oct. 2023, Somite.ai has raised over $10m to date.

Descope empowers developers to implement secure, seamless authentication and user experiences across diverse applications. Its platform focuses on enhancing application security while minimizing user friction, enabling businesses to adopt passwordless authentication with minimal coding effort.

Leo AI, established in 2023, specializes in a generative AI platform that streamlines mechanical product design. It converts textual descriptions, sketches, specifications, and CAD constraints into optimized, full-assembly 3D CAD models, significantly reducing engineering time and costs. Founded by experts from renowned institutions and tech companies, Leo AI aims to revolutionize the engineering design process.

JIT is a company that provides security software aimed at empowering developers to take control of the security aspects of their applications. Its innovative platform facilitates the adoption of a minimal viable security approach, helping development organizations adopt a just-in-time mindset. By focusing on the essential security measures necessary for web and cloud applications, JIT enables developers to manage risk and compliance efficiently as they progress with their projects. This allows developers to maintain their pace while ensuring that security is integrated into the development process from the outset.

Aktivate is a company that offers a software as a service (SaaS) technology platform designed to support K-12 schools in managing and funding scholastic sports programs. The platform includes administrative tools and engagement features that connect student-athletes, their families, schools, and partners. It provides resources for athletic directors, coaches, and parents, aiming to help students maximize their potential through sports while reducing financial barriers to participation. By facilitating transactions that are typically offline with a streamlined digital experience, Aktivate supports the broader sports community.

Somite.ai is a venture-backed company aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies. Somite's AI platform, AlphaStem, fuels a virtuous cycle: It enables new cell therapies, generating massive data that further improve the platform, empowering even faster therapy creation with broader applications. The company's pipeline includes the promising SMT-M01 program for Duchenne muscular dystrophy (DMD) and the SMT-B01 program for metabolic disorders. Incorporated in Oct. 2023, Somite.ai has raised over $10m to date.